ATRA and immunotherapy for advanced leiomyosarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs—all-trans retinoic acid (ATRA, a vitamin A derivative) and cemiplimab (an immunotherapy)—for people with advanced leiomyosarcoma who've already had chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have advanced leiomyosarcoma (a type of soft tissue cancer) that has spread or cannot be removed surgically.
- You've already had standard chemotherapy, with no limit on how many prior treatments.
- You should be able to swallow and keep down oral medications.
- Your blood counts, kidney, and liver function need to be within certain limits (your doctor will check these).
- You must not have active autoimmune disease or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called ivonescimab in people with leiomyosarcoma (a rare soft-tissue cancer) that cannot be surgically removed or has spread. The drug works by helping your immune system recognize and fight cancer cells.
This Phase 2 study tests a combination of three anti-cancer medicines to shrink or control leiomyosarcoma that cannot be fully removed by surgery or has spread. It may help people whose cancer has grown after prior treatment.
This trial tests a combination of immunotherapy (a treatment that helps your immune system attack cancer) and artificial intelligence (AI) technology as the first treatment for certain types of advanced soft tissue sarcoma. It aims to see if this approach can shrink tumors or stop them from growing better than current options.
This trial tests a new immune cell therapy (MASCT-I) combined with standard chemotherapy (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior chemotherapy or targeted therapy. The goal is to see if the combination works better than chemo alone.
This Phase 2 trial tests a highly focused radiation treatment to shrink sarcoma that has spread to a limited number of spots in the body. It may help control disease while limiting radiation to healthier tissue.
This Phase 3 study tests two anti-cancer medicines (anlotinib and catequentinib) for people with certain advanced soft-tissue sarcomas, including alveolar soft part sarcoma, synovial sarcoma, and leiomyosarcoma. It is designed for tumors that cannot be removed and that have either grown despite treatment or no longer respond to standard options.
Hear when a new Leiomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.